David Kirn, MD
David Kirn is a physician-scientist, entrepreneur, professor, translational and clinical therapeutics developer, and biopharmaceutical executive with over 25 years in the field. His research focuses on viral vector therapeutics at the intersection of product design, development, disease mechanisms (oncology, rare diseases), virology, translational and clinical R&D. As co-Founder & CEO of five companies focused on viral vector gene medicines, he’s helped to raise ~$350 million, executed over 10 business development partnerships internationally, and patient advocacy organizations. He was awarded the J&J Entrepreneur-Innovator Award in 2014. As an adjunct professor in BioEngineering at UC Berkeley, he teaches biotech entrepreneurship and therapeutics development. He was on the faculty of medicine at UCSF, Imperial College London, and Visiting Professor at Oxford University & Mayo Clinic. As an undergraduate at UC Berkeley he was awarded the Departmental Citation (top graduate) and Phi Beta Kappa. He did his medical training at UCSF (AOA) and Harvard (Chief Medical Resident), and business training at Haas Business School. He is senior author on over 100 biomedical publications including in Nature & Nature Medicine, and he’s given over 100 presentations.